PL1765391T3 - Kompozycje bakteryjne do leczenia nowotworów - Google Patents

Kompozycje bakteryjne do leczenia nowotworów

Info

Publication number
PL1765391T3
PL1765391T3 PL05748702T PL05748702T PL1765391T3 PL 1765391 T3 PL1765391 T3 PL 1765391T3 PL 05748702 T PL05748702 T PL 05748702T PL 05748702 T PL05748702 T PL 05748702T PL 1765391 T3 PL1765391 T3 PL 1765391T3
Authority
PL
Poland
Prior art keywords
cancer
treatment
bacterial compositions
bacterial
compositions
Prior art date
Application number
PL05748702T
Other languages
English (en)
Inventor
Harold D Gunn
Original Assignee
Qu Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qu Biologics Inc filed Critical Qu Biologics Inc
Publication of PL1765391T3 publication Critical patent/PL1765391T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/104—Pseudomonadales, e.g. Pseudomonas
    • A61K39/1045—Moraxella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05748702T 2004-06-07 2005-05-30 Kompozycje bakteryjne do leczenia nowotworów PL1765391T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57720604P 2004-06-07 2004-06-07
PCT/CA2005/000812 WO2005120560A1 (en) 2004-06-07 2005-05-30 Bacterial compositions for the treatment of cancer
EP05748702A EP1765391B1 (en) 2004-06-07 2005-05-30 Bacterial compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1765391T3 true PL1765391T3 (pl) 2013-08-30

Family

ID=35502832

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05748702T PL1765391T3 (pl) 2004-06-07 2005-05-30 Kompozycje bakteryjne do leczenia nowotworów

Country Status (11)

Country Link
US (1) US20070104733A1 (pl)
EP (3) EP2286832B1 (pl)
JP (5) JP5070051B2 (pl)
CN (1) CN101022826A (pl)
AU (2) AU2005251397B2 (pl)
CA (1) CA2611377C (pl)
DK (1) DK1765391T3 (pl)
ES (1) ES2404695T3 (pl)
NZ (2) NZ581806A (pl)
PL (1) PL1765391T3 (pl)
WO (1) WO2005120560A1 (pl)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR916101A0 (en) * 2001-11-28 2001-12-20 Bolin, Terry Dorcen Method of treating halitosis
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
NZ581806A (en) * 2004-06-07 2011-10-28 Qu Biolog Inc Bacterial compositions for the treatment of cancer
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
WO2007128838A1 (en) * 2006-05-10 2007-11-15 Institut National De La Recherche Agronomique Use of cells containing a specific dna molecule as cytopathic agents to inhibit the proliferation of cells
WO2008011884A1 (es) * 2006-07-27 2008-01-31 Ramirez Castro Angel Dr Nuevo inmunomodulador
NZ576590A (en) * 2006-10-27 2012-08-31 Qu Biolog Inc Tissue targeted antigenic activation of the immune response to treat cancers
CA2571805C (en) * 2006-10-27 2018-05-01 Harold David Gunn Tissue targeted antigenic activation of the immune response to cancers
US8980279B2 (en) 2010-07-26 2015-03-17 Qu Biologics Personalized site-specific immunomodulation
CN105816864A (zh) * 2010-07-26 2016-08-03 Qu生物制药公司 免疫原性抗炎组合物
EP4324526A3 (en) * 2010-07-26 2024-05-22 Qu Biologics Inc. Immunogenic anti-inflammatory compositions
JP2012180288A (ja) * 2011-02-28 2012-09-20 Morinaga Milk Ind Co Ltd 抗菌剤
JP5784327B2 (ja) * 2011-02-28 2015-09-24 森永乳業株式会社 抗菌剤
BRPI1100857A2 (pt) * 2011-03-18 2013-05-21 Alexandre Eduardo Nowill agente imunomodulador e suas combinaÇÕes, seu uso e mÉtodo imunoterÁpico para a recontextualizaÇço, reprogramaÇço e reconduÇço do sistema imune em tempo real
US9844592B2 (en) 2011-07-18 2017-12-19 Icahn School Of Medicine At Mount Sinai Bacterial RNAs as vaccine adjuvants
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
CN104884073B (zh) * 2013-01-02 2019-07-12 迪卡奥艾生物系统有限公司 使用细菌治疗癌症的组合物和方法
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
CA2947631A1 (en) * 2014-05-02 2015-11-05 Qu Biologics Inc. Anti-microbial immunomodulation
ES2842748T3 (es) 2014-11-10 2021-07-14 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Escherichia coli patogénica atenuada o inactivada para el tratamiento del cáncer urogenital
PL3193901T3 (pl) 2014-12-23 2018-10-31 4D Pharma Research Limited Polipeptyd pyrynowy i immunomodulacja
CN113862175A (zh) 2014-12-23 2021-12-31 4D制药研究有限公司 免疫调控
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
RS59446B1 (sr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Blautia stercosis i wexlerae za upotrebu u lečenju inflamatornih i autoimunskih bolesti
PE20180267A1 (es) 2015-06-15 2018-02-06 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MD3206700T2 (ro) 2015-06-15 2019-12-31 4D Pharma Res Ltd Compoziții conținând tulpini bacteriene
WO2017074257A1 (en) * 2015-10-26 2017-05-04 Nanyang Technological University Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents
WO2017085520A1 (en) 2015-11-20 2017-05-26 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6441536B2 (ja) 2016-03-04 2018-12-19 フォーディー ファーマ ピーエルシー４Ｄ Ｐｈａｒｍａ Ｐｌｃ 細菌株を含む組成物
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3448397A4 (en) 2016-04-26 2020-01-08 Qu Biologics Inc. THERAPEUTIC INITIATION OF A BORN IMMUNE RESPONSE IN A TARGET TISSUE
CN106011007A (zh) * 2016-06-06 2016-10-12 余国华 多联耐药菌免疫活性蛋白及其制备方法和用途
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
WO2018215782A1 (en) 2017-05-24 2018-11-29 4D Pharma Research Limited Compositions comprising bacterial strain
LT3600363T (lt) 2017-06-14 2021-02-10 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
MA49010B1 (fr) 2017-06-14 2020-11-30 4D Pharma Res Ltd Compositions comprenant une souche bactérienne du genre megasphaera et leurs utilisations
CN109793761B (zh) * 2017-11-17 2021-03-05 瑞微（深圳）生物科技有限公司 一种用于增强t细胞免疫功能的组合物及其制备方法
CA3086832A1 (en) 2018-01-03 2019-07-11 Qu Biologics Inc. Innate targeting of adoptive cellular therapies
KR102095355B1 (ko) 2018-01-12 2020-03-31 주식회사 엠디헬스케어 모르가넬라 속 세균 유래 나노소포 및 이의 용도
WO2020006216A1 (en) * 2018-06-27 2020-01-02 Evelo Biosciences, Inc. Compositions and methods of treating cancer using neisseria bacteria
CA3152931A1 (en) * 2019-09-30 2021-04-08 Erik Eastlund Modulation of microbiota compositions using targeted nucleases
JP7153274B2 (ja) * 2019-12-25 2022-10-14 京都府公立大学法人 慢性腎臓病進行抑制剤
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
US12257273B2 (en) 2020-12-14 2025-03-25 Trim Biotech, S.L. Compositions comprising bacteria for cancer immunotherapy
US20240091277A1 (en) * 2021-03-24 2024-03-21 Qu Biologics Inc. Perioperative Innate Immune Priming in Cancer Therapy
WO2023021353A1 (en) * 2021-08-17 2023-02-23 Fondazione Per L’Istituto Oncologico Di Ricerca (Ior) Commensal bacteria promote endocrine-resistance in prostate cancer via androgen biosynthesis
CN115671140B (zh) * 2022-10-31 2024-03-22 华中科技大学同济医学院附属同济医院 丙酸痤疮杆菌在制备治疗鼻息肉的药品中的应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928565A (en) * 1971-10-19 1975-12-23 Yuzuru Homma Pharmaceutical preparation of pseudomonas aeruginosa bacterial component possessing anti-tumor and anti-infection properties
JPS5946493B2 (ja) * 1978-03-31 1984-11-13 株式会社三和化学研究所 異種死菌体混合物を有効成分とする抗腫瘍剤
JPS568320A (en) * 1979-07-04 1981-01-28 Chisato Maruyama Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
JPS56108716A (en) * 1980-01-30 1981-08-28 Sanwa Kagaku Kenkyusho:Kk Antiviral agent containing different kind dead cell mixture as effective component
JPS5839624A (ja) * 1981-09-02 1983-03-08 Meiji Seika Kaisha Ltd 抗腫瘍剤
JPS6012071A (ja) * 1983-06-30 1985-01-22 東レ株式会社 抗腫瘍作用を有する体液処理剤
JPS6048929A (ja) * 1983-08-26 1985-03-16 Chugai Pharmaceut Co Ltd 抗腫瘍剤
JPS6272623A (ja) * 1985-09-26 1987-04-03 Sekisui Chem Co Ltd 悪性腫瘍等の治療方法
JPH0742233B2 (ja) * 1987-02-20 1995-05-10 東レ株式会社 血液処理剤
US5292513A (en) * 1992-05-18 1994-03-08 Anthony G. Gristina Method for nonspecific cellular immune stimulation
GB9406301D0 (en) * 1994-03-30 1994-05-25 Univ London Immunotherapeutic agent and its use
US6190657B1 (en) * 1995-06-07 2001-02-20 Yale University Vectors for the diagnosis and treatment of solid tumors including melanoma
US20020128240A1 (en) * 1996-12-30 2002-09-12 Bone Care International, Inc. Treatment of hyperproliferative diseases using active vitamin D analogues
CN1253551C (zh) * 1997-09-10 2006-04-26 维昂药品公司 减毒的遗传修饰肿瘤靶向细菌
EP1064000B1 (en) * 1998-03-27 2011-07-06 Oregon Health & Science University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
WO2001056387A1 (en) * 2000-02-01 2001-08-09 Donnell Michael A O Immunotherapeutic treatment methodology for patients afflicted with superficial bladder cancer who previously failed at least one immunostimulatory therapeutic treatment regimen
TWI306760B (en) * 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
JP4859341B2 (ja) * 2001-07-19 2012-01-25 昭 林 ヒト免疫療法
AU2002353366A1 (en) * 2001-12-10 2003-06-23 Bakulesh Mafatlal Khamar The process of manufacturing a pharmaceutical composition useful for management of cancer
PT1461054E (pt) * 2001-12-11 2010-08-09 Pasteur Institut Preparações de bactérias gram positivas para o tratamento de doenças que implicam uma desregulação imunitária
WO2003063593A1 (en) * 2002-01-28 2003-08-07 Vion Pharmaceuticals, Inc. Methods for treating cancer by administering tumor-targetted bacteria and an immunomodulatory agent
NZ581806A (en) * 2004-06-07 2011-10-28 Qu Biolog Inc Bacterial compositions for the treatment of cancer

Also Published As

Publication number Publication date
NZ586338A (en) 2012-02-24
US20070104733A1 (en) 2007-05-10
EP2801371A1 (en) 2014-11-12
EP2286832A1 (en) 2011-02-23
JP5783915B2 (ja) 2015-09-24
EP1765391B1 (en) 2013-03-06
WO2005120560A1 (en) 2005-12-22
EP1765391A1 (en) 2007-03-28
EP2801371B1 (en) 2016-09-21
CA2611377C (en) 2019-04-09
AU2005251397A1 (en) 2005-12-22
JP2016006084A (ja) 2016-01-14
DK1765391T3 (da) 2013-03-25
JP5070051B2 (ja) 2012-11-07
JP2014077011A (ja) 2014-05-01
AU2011200580B2 (en) 2012-09-27
CA2611377A1 (en) 2005-12-22
AU2005251397B2 (en) 2010-11-11
JP2015157848A (ja) 2015-09-03
AU2011200580A1 (en) 2011-03-03
EP2286832B1 (en) 2014-07-23
JP6093410B2 (ja) 2017-03-08
JP2012097112A (ja) 2012-05-24
ES2404695T3 (es) 2013-05-28
EP1765391A4 (en) 2008-02-13
JP6051261B2 (ja) 2016-12-27
JP5784103B2 (ja) 2015-09-24
JP2008501728A (ja) 2008-01-24
NZ581806A (en) 2011-10-28
CN101022826A (zh) 2007-08-22

Similar Documents

Publication Publication Date Title
PL1765391T3 (pl) Kompozycje bakteryjne do leczenia nowotworów
IL190882A0 (en) Compositions for cancer therapy
IL188746A0 (en) Treatment of cancer
IL191832A0 (en) Pyridiazinone derivatives for the treatment of tumours
IL227841A0 (en) Dihydropyridinones for the treatment of cancer
IL188430A0 (en) Treatment of tumors
ZA200904492B (en) Compositions and methods for the treatment of infections and tumors
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
EP1830847A4 (en) ANTICANCER TREATMENT
EP1979487A4 (en) COBALAMINE COMPOSITIONS FOR THE TREATMENT OF CANCER
IL179129A0 (en) Kit for treatment of cancer
GB0428187D0 (en) Cancer treatment
IL187792A0 (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0517387D0 (en) Combinations for the treatment of cancer
ZA200805522B (en) Dioxoiane dérivates for the treatment of cancer
IL175689A0 (en) Enoxaparin for the treatment of cancer
GB0520067D0 (en) Treatment of cancer
IL180709A0 (en) Treatment of tumours
GB0410379D0 (en) Treatment of cancer
GB0404675D0 (en) Cancer treatment
GB0423273D0 (en) Treatment of cancer
HU0500947D0 (en) Composition for treatment of paradontosis
GB0517386D0 (en) Combinations for the treatment of cancer
HK1109394A (en) Pyrazolylamino substituted quinazoles for the treatment of cancer
HK1113749A (en) 4-anilino-3-quinolinecarbonitriles for the treatment of cancer